Lipid metabolism during treatment of endometriosis with the progestin dienogest
Non-randomised trial
OA: closed
CC0
⤵ 17 in-corpus citations
AI-generated summary
Treatment of endometriosis with dienogest for 24 weeks resulted in minor decreases in HDL-cholesterol and triglycerides, a transient increase in LDL-cholesterol, and a slight rise in the LDL/HDL ratio.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The effects of a new progestational compound, dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on lipid metabolism have been studied in 84 otherwise healthy women with laparoscopically proven endometriosis. The women, aged 17 to 45, years were treated with 2 mg dienogest in tablet form daily for 24 weeks. The progestin was highly effective on endometriotic lesions and symptoms, showing an objective endoscopic and a subjective symptomatic improvement in 80% and 83% respectively. Triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol and the LDL-cholesterol/HDL-cholesterol ratio were determined before and after 1, 3 and 6 months use of the progestin. There was a maximum decrease of -5.8% in HDL-cholesterol and of -6.5% in triglycerides after 6 months of therapy vis-à-vis the pretreatment values. The maximum increase in LDL-cholesterol of +5.0% was recorded by the end of the first month of dienogest ingestion. The LDL-cholesterol/HDL-cholesterol ratio rose from 1.6 to 1.8 during the course of therapy. There were no significant changes. The data suggest that 2 mg dienogest has little influence on lipid metabolism and provides also in this respect a suitable approach to the hormonal therapy of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (11)
- Carbohydrate metabolism during treatment of endometriosis with the progestin dienogest via openalex
- Changes of plasma lipids and lipoprotein levels during danazol treatment for endometriosis via openalex
- Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan via openalex
- Effects of danazol on plasma lipid and lipoprotein levels in healthy women and in women with endometriosis via openalex
- [Lipoprotein changes during hormonal treatment of endometriosis with lynestrenol and danazol] via openalex
- Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate via openalex
- Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate via openalex
- [Metabolic effects and general side effects in the treatment of endometriosis with an LHRH agonist] via openalex
- Plasma lipoproteins during and after danazol treatment via openalex
- W2116404316 via openalex
- doi:10.1055/s-0029-1210764 via openalex
Cited by (17)
- Drug development for adenomyosis based on pathophysiology 2025
- Correlation between lipid metabolism and endometriosis: a meta-analysis 2025
- Long-term Health Consequences of Endometriosis - Pathways and Mediation by Treatment 2020
- The experience of Visanne use in patients of reproductive age with external genital endometriosis 2016
- Dienogest in the treatment of endometriosis 2014
- Dienogest (DNG) in der Therapie der Endometriose Übersicht zur aktuellen Studienlage 2011
- Dienogest: a review of its use in the treatment of endometriosis 2010
- Dienogest: an oral progestogen for the treatment of endometriosis 2010
- Ethinylestradiol/dienogest in oral contraception 2010
- Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study 2010
- A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis 2009
- Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells 2007
- The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro 2001
- Dienogest 1998
- Reappraisal of progestins in endometriosis therapy 1998
- Progestins for symptomatic endometriosis: a critical analysis of the evidence 1997
- Changing concepts of medical treatment of endometriosis 1993
Source provenance
- europepmc
- last seen: 2026-10-09T06:09:53.026058+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:16:08.491429+00:00
- unpaywall
- last seen: 2026-10-09T06:36:44.367587+00:00
License: CC0
· commercial use OK